



A META-ANALYSIS OF OPTIMAL ANTIBIOTIC TREATMENT DURATION FOR UNCOMPLICATED UTIs: BALANCING EFFICACY AND RESISTANCE

Dr Izaz Ahmad¹, Dr Saad², Dr Haroon Ahmad³, Dr Arshad Mehmood⁴, Dr Junaid Ahmad⁵, Dr Ameer Hamza⁶, Dr Syed Aizaz Ur Rahman⁷, Dr Zubair Ahmad^{8*}, Dr Mohammad Abbas⁹, Dr Muhammad Abbas¹⁰

¹Resident Physician, Internal Medicine, Medical A Unit, Lady Reading Hospital, Peshawar

²Postgraduate resident, Medical speciality group A, Lady Reading Hospital Peshawar

³Senior House Officer, Rehman Medical Institute, Hayatabad, Peshawar

⁴Resident Physician, General Medicine, Medical B ward, Hayatabad Medical Complex, Peshawar, Pakistan

⁵House officer, Medicine, Hayatabad Medical Complex, Peshawar

⁶Resident training medical officer, Internal medicine, MTI-Mardan medical complex

⁷Resident Physician, Medicine, Mardan Medical complex, MTI Mardan

^{8*}Resident Physician, Internal Medicine, Medical C ward, Hayat Abad Medical Complex

⁹Medical officer, pediatric oncology, shaukat khanum memorial hospital and research center, Peshawar

¹⁰Resident Physician, Speciality Group A, Medical A ward, Hayat Abad Medical Complex, Peshawar

***Corresponding Author:** Dr Zubair Ahmad

*Resident Physician, Internal Medicine, Medical C ward, Hayat Abad Medical Complex

Email Address: dr.zubair1193@gmail.com

Abstract

Background: Patients typically encounter simple urinary tract infections in hospital settings. An increasing number of research studies are evaluating the most efficient approaches to treatment for uncomplicated UTIs. Comparing the outcomes of various trials is tricky because the reported results are diverse.

Objective: Identify the essential outcomes that systematic reviews of therapies and trials for the action of uncomplicated UTIs in adults must document.

Methods: We conducted a methodical investigation to identify the fundamental outcomes commonly used to assess the effectiveness of UTI therapies. We conducted a comprehensive search in the Library Cochrane of Systematic Reviews, Embase, and PubMed. A single scholar conducted an initial screening of each paper for eligibility, while the COSUTI team served as secondary reviewers. All the included papers underwent screening by two reviewers. We extracted the outcomes exactly as stated, categorizing any identical outcomes into subdomains and domains.

Results: 14 studies documented a total of 334 outcomes, with an average of 8 outcomes reported per paper. We classified the outcomes into 18 areas, most of which were associated with clinical cure results. We measured and reported a wide range of outcomes at different time points.

Conclusions: Currently, comparing the results of trials studying the simple treatment of UTIs presents a challenge due to the variation in reported outcomes. Establishing a standardized set of outcomes to record in all trials is advisable to enhance the consistency of outcome reporting.

Introduction

Urinary tract infections (UTIs) are some of the most common infections in the outpatient environment, with significant implications for individuals and society in terms of illness and mortality. There are two categories of UTIs: simple and complex. Uropathogenic *Escherichia coli* (UPEC) (Peerayeh, 2018), a gram-negative bacterium, is the major etiologic pathogen in both cases, although we cannot ignore the existence of gram-positive fungi and bacteria. Uncomplicated UTI is a sudden episode of bladder inflammation or infection in an adult, but it presents with no structural or functional abnormality within the urinary tract infections. A complicated UTI, on the other hand, has structural or functional abnormalities in the UTIs that place a patient at an increased risk of life-threatening or treatment failure difficulties. For instance, the majority of UTIs are specific to age and gender, and their prevalence and distribution vary. The prevalence of UTIs is higher in females compared to the numbers in males (Seifu, 2018). Clinical statistics indicate that nearly every woman will experience at least one urinary tract infection (UTI) in her lifetime. By the time they are 24 years old, which is the mean age, all women will have received antibiotics for UTI treatment, and one out of three will have had a doctor's diagnosis and prescription. Researchers have also conducted international clinical trials to determine the most effective therapeutic alternatives for treating uncomplicated UTIs. Researchers assess the effects of medicinal, surgical, or behavioral interventions on human health outcomes in this scientific study. Because of the inconsistency in reporting outcomes, it is difficult to derive a comparative analysis from clinical trial results. This defect limits the likelihood of evidence synthesis being reliable for healthcare decision-making. The goal of a COS is to resolve issues related to selective outcome reporting bias, assist in improved information synthesis, and reconcile inconsistencies within the literature. Studies involving any medical condition should measure and report a COS, a set of predefined outcomes. Clinical studies assessing the safety and effectiveness of treatments for uncomplicated UTI in adults have not developed a COS. However, the COSUTI project intends to fill this knowledge gap with respect to UTI management. To set the stage, there is a need to have a complete evaluation of the treatment outcomes published to date in clinical trials. The present systematic review hopes to offer a full list of the studies that either entirely or partially describe the results of clinical trials carried out in adult patients with the aim of treating uncomplicated UTIs. In this study, the definition of uncomplicated UTIs is the abrupt dysuria of onset, or urgency, frequency, in a non-pregnant woman or healthy man in whom there are no known anatomical or present functional abnormalities (Ray, 2016).

Methods

The inclusion criteria for review involved randomized studies and trials of systematic reviews, including those deprived of meta-analyses. The purpose of review was to evaluate the effectiveness of various therapies in treating adult patients with uncomplicated UTIs or cystitis, who were generally considered healthy. We excluded recurrent UTIs or pyelonephritis from this comparison because they don't directly align with the research objectives. We searched the last 10 years within the Systematic Reviews of Cochrane Framework, along with PubMed and Embase, using a search terms of combination to identify relevant papers published from 2007 to 2017. Search terms included (UTIs), RCTs, cystitis, clinical trials controlled, randomization, placebos, and trials. The complete search technique can be found in the COSUTI protocol. We applied a 10-year search period to confirm the results accurately reproduced current therapies. We limited our search to English papers only. Two reviewers independently screened abstracts and titles, followed by full-text articles for potentially relevant articles. We consulted additional reviewers as needed for clarification. We extracted the outcomes verbatim and sorted them into domains using paired comparison. We further categorized the outcomes into subdomains as needed to cluster like-

outcomes into general themes. When completed, the COSUTI team fact-checked each outcome and its domain classification. We examined the patterns of result journalism, taking into account the number of studies conducted, their rate, and the definition of outcome reporting within the reporting period, as well as the reproducibility of the reported outcomes. This review, designed in compliance with both the PRISMA and the COMET guidelines, will document and report correctly on methods and results.

Results

Study selection

We have identified a total of 8741 documents across the four databases. After eliminating duplicate entries, a total of 6311 entries remained qualified for title and abstract showing. We eliminated an additional 6175 papers during the title and abstract review process. We omitted most studies due to their focus on therapies for complex urinary tract infections, recurring urinary tract infections, or pediatric cases. We also excluded experiments conducted on animals and other diseases. Upon completion of the title screening process, we deemed a total of 134 studies suitable for full text screening. The reasons specified in Figure 1 led to the rejection of an additional 92 studies. Various reasons led to the rejection of a number of papers, including their patient population not meeting the desired sample size ($n = 21$), their unavailability in English ($n = 10$), their duplication of other studies ($n = 7$), their only availability in abstract form ($n = 21$), their affiliation with a different project ($n = 5$ or 12), their status as a discussion article ($n = 3$), and their failure to report any results ($n = 1$). A total of 39 included studies were in the process of data extraction. Figure 1 provides a concise overview of the COSUTI PRISMA.

Attributes of research investigations


We have identified a total of 8741 documents across the four databases. After eliminating duplicate entries, a total of 6311 entries remained qualified for title and abstract showing. We eliminated an additional 6175 papers during the title and abstract review processes. We omitted most studies due to their focus on therapies for complex urinary tract infections, recurring urinary tract infections, or pediatric cases. We also excluded experiments conducted on animals and other diseases. Upon completion of the title screening process, we deemed a total of 134 studies suitable for full text screening. The reasons specified in Figure 1 led to the rejection of an additional 92 studies. Various reasons led to the rejection of a number of papers, including their patient population not meeting the desired sample size ($n = 21$), their unavailability in English ($n = 10$), their duplication of other studies ($n = 7$), their only availability in abstract form ($n = 21$), their affiliation with a different project ($n = 5$ or 12), their status as a discussion article ($n = 3$), and their failure to report any results ($n = 1$). A total of 39 included studies were in the process of data extraction. Figure 1 provides a concise overview of the COSUTI PRISMA.

Adverse treatment complications and reactions

The adverse treatment of domain responses and complications had the highest number of reported outcomes, with 25 and 17 outcomes, respectively. These areas recorded a variety of results, and the trials displayed discrepancies in reporting adverse reactions and complications. These inconsistencies highlight the difficulties of reporting these outcomes accurately and uniformly. Occasionally, the documentation of each negative response or treatment-related problem as an individual trial result occurred.

Quality of life

Most of the trials did not assess life quality outcomes. Five studies included measures of quality of life outcomes, such as assessing patients' self-reported life quality and their mental health status. Additionally, three studies assessed absence after work as an outcome.



Time points

Eight of the 18 domains, assessed or reported at various time intervals, had comparable results. The presence of a diverse range of time points in reported outcomes has led to a general rise in the total number of reported outcomes. For example, the relapse domain encompassed outcomes associated with the return or reappearance of UTI symptoms after the first remission. Thirteen out of 16 results in this category provided a specific timepoint. The reported time intervals varied from brief “14 days” to extended “1 year” durations. The outcomes that lacked a specific time frame were temporally extensive, such as corrosion occurring after the initial alleviation of symptoms, and were associated with determining the timing of a recurrence. Table 3 classifies seven results as clinical cures. These outcomes pertain to the temporal aspects of clinical cure, specifically the clinical cure after therapy commencement, completion of treatment, and follow-up. This emphasizes the need for trial participants to evaluate management results at various intervals. Nevertheless, the absence of consistency and duplication in the dates of treatment commencement and completion may further lead to difficulties in merging study findings.

Table 1. Summarizes the goals and actions taken in the studies that are included.

First author	Objective	Intervention
“ (Dawson-Hahn EE, 2017)”	This study evaluates the effectiveness of short-term versus and long-term regimens oral antibiotic for treating poisons in non-hospital situations.	Both little and extended durations of oral antibiotics.
“ (Drozdov D, 2013)”	Intervention A will study the antibiotic response in patients treated for urinary tract infections (UTIs), considering the kind of (UTI), pyuria, and procalcitonin levels. Intervention B will evaluate the effectiveness of adding the biomarker prognostic to an assessment interdisciplinary roll to improve decision-making regarding care locations.	Intervention A aims to assess the effectiveness and safety of a treatment strategy that uses procalcitonin and pyuria to guide antibiotic therapy. The goal is to personalize and shorten period of antibiotic cure, and compare it with the guidelines standard.
“ (Deepalatha C, 2011)”	We aim to evaluate the effectiveness of pain management in reducing the burning sensation and discomfort during urination within 48 hours of	The first group consists of phenazopyridine, which is combined with an antibiotic. The second group is called Cystone.

	diagnosing a basic urinary tract infection (UTI).	
“(Gagyor I, 2012)”	This study explores the potential for reducing antibiotic use in treating simple urinary tract infections (UTIs) by initially using ibuprofen as a treatment.	Patients who are involved in the study are given either rapid antibiotic rehabilitation with initial indicative behavior or FMT 1×3 g with ibuprofen (3×400) mg for period of 3 days.
“(Gágyor I, 2015)”	Can managing the uncomplicated UTIs symptoms of an with ibuprofen decrease antibiotic treatments without significantly increasing symptoms, complications, or returns?	A single administration of fosfomycin 3 g (n=246; 243 subjects analysed) or ibuprofen 3× 400 mg (n=248; 241 subjects analysed) for a duration of 3 days (together with corresponding placebo treatments in both groups)
“(Grabein B, 2017)”	We aim to provide a concise summary of the experimental data and usage developments of intravenous fosfomycin, from its origins to the current day.	Intravenous fosfomycin
“(Grigoryan L, 2014)”	The objective is to identify the most effective treatment strategies for managing acute cystitis in fresh, women by diabetes, men, and healthy women. Additionally, we aim to establish the best diagnostic style for identifying critical cystitis in an patient situation.	Analysis and treatment of urinary tract infections
“(Gutiérrez-Castrellón P, 2015)”	We performed a comprehensive analysis, including a meta-analysis of randomized controlled trials, to assess the success and care of ciprofloxacin in treating acute or severe urinary tract infections (UTIs) in individuals.	Ciprofloxacin is used to treat acute or complex urinary tract infections (UTIs) in humans.
“(Sadahira T, 2017)”	The study aims to assess the microbiological and clinical effectiveness of pivoxil cefditoren in discussing acute uncomplicated cystitis. Additionally, it seeks to determine the appropriate treatment duration for this medication.	A randomised trial was conducted to evaluate the microbiological efficacies and the clinical of cefditoren pivoxil for the usage of acute uncomplicated cystitis. The study assessed the effectiveness of both 3-day and 7-day regimens.
“(Stange R, 2017)”	The goal is to demonstrate that a herbal combination of nasturtium herb and horseradish root is as effective as the antibiotic co-trimoxazole in treating severe, uncomplicated cystitis.	Patients were either the combination of herbal, the antibiotic, consisting of two tablets taken daily, or consisting of five pills taken 4 times a day, for a duration of 3 or 7 days, individually. This was followed by a 21-day period without any medication treatment. Placebos were used to ensure blindness.
“(Trill J, 2017)”	This study aims to determine if using NSAIDs or the herbal medication uva-ursi can alleviate urinary symptoms and reduce antibiotics the need for in adult women with suspected UTIs who agree to a delayed prescription strategy.	Group 1 will receive uva-ursi and be advised to revenue ibuprofen. Group 2 will receive a placebo and be advised to take ibuprofen. Group 3 will receive uva-ursi and be advised not to use ibuprofen. Group 4 will receive a placebo and no instructions to take ibuprofen.
“(Trestioreanu A Z, 2010)”	We aim to evaluate the effectiveness of ibuprofen and mecillinam in managing uncomplicated cystitis in well, adult women non-pregnant.	A relative study remained conducted to evaluate the success of ibuprofen and mecillinam in treating uncomplicated cystitis in strong, non-pregnant adult women.
“(Trestioreanu A Z, 2010)”	This study aims to assess the effectiveness, safety of various antimicrobial therapies for acute uncomplicated lower urinary tract infections (UTIs), and resistance development.	Various antibiotic therapies for acute uncomplicated lower (UTIs)
“(Masson P, 2009)”	The goal is to use meta-analyses to evaluate existing recommendations for the treatment of urinary tract infections and prevention in both children and adults.	Therapies for Urinary Tract Infections

Table 2: A summary of the quantity of outcomes submitted

Domain	No. of outcomes	Sub domain
Antibiotic use	2	Antibiotic
	1	Treatment duration
Symptom resolution	12	Symptom resolution
Clinical cure	7	Clinical cure
Complications	17	Complications
Symptoms	3	Duration
	2	Symptom severity
	5	Overall symptoms
Relapse	16	Relapse

Adverse treatment reactions	25	Adverse treatment reactions
Failure	4	Failure
	1	Secondary antibiotics
	4	Re-consultation
Discontinuation	1	Discontinuation
Pyuria	1	Pyuria (P)
Quality of life	7	Quality of life
Tolerance	1	Adherence
Antibiotic resistance	1	Antibiotic resistance
Patient satisfaction	2	Satisfaction
Microbiological cure	1	Microbiological cure
Bacterial cure	3	Bacterial cure
Microbiological failure	5	(MF)
Microbiological relapse	3	(MR)

Table 3. Domain of clinical cure

- Clinical recovery Experimental recovery by Day 4 following therapy commencement.
- Clinical recovery by Day 7 after starting therapy.
- Clinical recovery five to nine days following therapy completion.
- clinical recovery three weeks following the end of the treatment clinical recovery 4-6 weeks following check-in the end of the treatment Medical recovery by the 30-day.

Discussion

This systematic review of the treatment of uncomplicated urinary tract infections revealed a great deal of inconsistency in the availability of definitions and methods to measure the treatment effect. We measured a total of 124 outcomes across 18 different outcome domains. The high burden of symptoms experienced in urinary tract infection results in unclear definitions of important aspects, such as 'clinical cure'; as a result, the timing of outcome measurement is not consistent. The absence of clear descriptions of the timepoints and the rationale behind their selection makes it difficult to determine the appropriate timepoint for reporting many of the results. In order to standardize trial evidence reporting and increase the ability to synthesize findings in this area, a core outcome set should be agreed upon. It would also reduce the collection of outcomes and measurement that are less of importance to those who have an interest in this research area. This review aims to describe the currently reported outcomes, not synthesize the findings of the included trials. It is important to clearly define that the definition of uncomplicated UTI in this article differs from the FDA's guidelines for developing medications to treat uncomplicated UTI and from the IDSA/ESCMID's treatment guidelines for uncomplicated UTI, as it includes male individuals. The study focused on adult patient populations, which includes both male and female individuals.

Summary

UTI treatment is a major contributor to the administration of antibiotics in medical care, as it is the second most prevalent infection seen in primary care. It accounts for around 15%–20% of all antibiotic prescriptions. In light of the escalating battle against antibiotic resistance, it is crucial to persist in the quest for viable and secure alternative therapies to antibiotics for urinary tract infections (UTI). The trials examining the optimal treatments for UTI, whether finished or ongoing, have little impact in this field due to the large number and diverse range of outcomes currently being reported. This systematic study emphasizes the inconsistencies regarding the prioritization of outcomes and the timing of their reporting. This impedes the synthesis of evidence in this field. In order to enhance uniformity, it is necessary to create a consistent collection of results to document trials examining the efficacy of treatments for urinary tract infections and the synthesis of data. The upcoming stage of COSUTI will concentrate on the creation of a fundamental set of outcomes to tackle this deficiency in research.

References

1. Dawson-Hahn EE, M. S. (2017). Short-course versus long-course oral antibiotic treatment for infections treated in outpatient settings: a review of systematic reviews . *Fam Pract*, 34: 511–9.
2. Deepalatha C, D. N. (2011). A comparative study of phenazopyridine (Pyridium) and Cystone as short-term analgesic in uncomplicated urinary tract infection 3 Suppl . *Int J Pharm Pharm Sci*, 2: 224–6.
3. Drozdov D, T. A. (2013). Procalcitonin, pyuria and proadrenomedullin in the management of urinary tract infections - ‘triple p in uti’: study protocol for a randomized controlled trial. *Trials* , 14: 84.
4. Gágyor I, B. J. (2015). Ibuprofen versus fosfomycin for uncomplicated urinary tract infection in women: randomised controlled trial. *BMJ* , 351: h6544.
5. Gagyor I, H.-P. E. (2012). Immediate versus conditional treatment of uncomplicated urinary tract infection - a randomized-controlled comparative effectiveness study in general practices. *BMC Infect Dis* , 28: 146.
6. Grabein B, G. W. (2017). Intravenous fosfomycin-back to the future. Systematic review and meta-analysis of the clinical literature. *Clin Microbiol Infect*, 23: 363–72.
7. Grigoryan L, T. B. (2014). Diagnosis and management of urinary tract infections in the outpatient setting: a review. . *JAMA* , 312: 1677–84.
8. Gutiérrez-Castrellón P, D.-G. L.-R. (2015). [Efficacy and safety of ciprofloxacin in the treatment of urinary tract infections (UTIs) in adults: a systematic review with meta-analysis . *Gac Med Mex* , 151: 225–44.
9. Masson P, M. S. (2009). Meta-analyses in prevention and treatment of urinary tract infections. *Infect Dis Clin North Am*, 23: 355–85.
10. Peerayeh, S. N. (2018). Pathogenicity determinants and epidemiology of uropathogenic E. coli (UPEC) strains isolated from children with urinary tract infection (UTI) to define distinct pathotypes. . *Biomed Res*, 29(10), 2035-43.
11. Ray, J. G. (2016). Association between MRI exposure during pregnancy and fetal and childhood outcomes. *Jama*, 316(9), 952-961.
12. Sadahira T, W. K. (2017). Efficacy and safety of 3 day versus 7 day cefditoren pivoxil regimens for acute uncomplicated cystitis: multicentre, randomized, open-label trial. *J Antimicrob Chemother* , 72: 529–34.
13. Seifu, W. D. (2018). Prevalence and antibiotic susceptibility of Uropathogens from cases of urinary tract infections (UTI) in Shashemene referral hospital, Ethiopia . *BMC infectious diseases*, 18, 1-9.
14. Stange R, S. B. (2017). *Res Rep Urol* .
15. Stange R, S. B. (2017). Results of a randomized, prospective, double-dummy, double-blind trial to compare efficacy and safety of a herbal combination containing *Tropaeoli majoris herba* and *Armoraciae rusticanae radix* with co-trimoxazole . *Res Rep Urol* , 9: 43–50.
16. Trestioreanu A Z, G. H. (2010). Antimicrobial agents for treating uncomplicated urinary tract infection in women. *Cochrane Database Syst Rev*, CD007182.
17. Trill J, S. C. (2017). Uva-ursi extract and ibuprofen as alternative treatments of adult female urinary tract infection (ATAFUTI): study protocol for a randomised controlled trial. *Trials*, 18: 421.